Ticker Notes
A collection of stock notes from around the web.
November 6, 2008
$28 Price Target on Osiris
Zacks is out
with a $28 price target on Osiris Therapeutics after the company announced a partnership with Genzyme in developing two late-stage adult stem-cell treatments.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment